Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 7835533

Polycyclic aromatic hydrocarbons decrease intracellular glutathione levels in the A20.1 murine B cell lymphoma.

J W Yuan·J A Krieger·K R Maples·J L Born·S W Burchiel
View original source ↗Export metadata ↓

Abstract

Previous studies in this laboratory have shown that polycyclic aromatic hydrocarbons (PAHs) inhibit lymphocyte activation and alter intracellular Ca2+ homeostasis. Other investigators have demonstrated that intracellular Ca2+ may increase in lymphocytes following exposure to chemical oxidants or ionizing radiation. Cellular oxidants produce both a rise in intracellular Ca2+ and a decrease in intracellular levels of glutathione (GSH) in numerous cells and tissues. Therefore, the purpose of the present study was to determine whether PAHs alter intracellular levels of glutathione in lymphocytes. Using different, well-established glutathione assays, it was demonstrated in the A20.1 murine B lymphoma that PAHs induce a transient decrease in intracellular glutathione. A 10-25% decrease in reduced GSH was produced by benzo(a)pyrene, 7,12-dimethylbenz(a)anthracene, benz(a)anthracene, and anthracene within 2-4 hr of exposure. Benzo(e)pyrene did not alter intracellular levels of glutathione in A20.1 cells. We conclude that glutathione depletion may contribute to cell injury in lymphocytes exposed to PAHs.

Explore related subjects

9,10-Dimethyl-1,2-benzanthraceneAnimalsBenz(a)AnthracenesBenzo(a)pyreneCalciumChromatography, High Pressure LiquidDose-Response Relationship, DrugGlutathioneLymphoma, B-CellMicePolycyclic CompoundsTumor Cells, CulturedJournal ArticleResearch Support, U.S. Gov't, P.H.S.

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J W Yuan, J A Krieger, K R Maples, J L Born, S W Burchiel. 1994. Polycyclic aromatic hydrocarbons decrease intracellular glutathione levels in the A20.1 murine B cell lymphoma.. https://doi.org/10.1006/faat.1994.1113

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1996

Bacterial photomutagenicity testing: distinction between direct, enzyme-mediated and light-induced events.

A bacterial photomutagenicity test system has been established according to a predetermined protocol using a light source emitting multiple wave lengths, including UV-A and UV-B, and the tester strains used for standard bacterial mutagenicity testing. 8-Methoxypsoralen (8-MOP) was used as a photomutagenic positive control showing no mutagenicity in the absence of light and borderline (Salmonella typhimurium TA1537) or clear (Salmonella typhimurium TA102 and Escherichia coli WP2) mutagenic effects in the presence of light. Using the same experimental conditions, the UV filters p-aminobenzoic acid (PABA), octyl dimethyl PABA (Eusolex 6007), and 4-methylbenzylidene camphor (Eusolex 6300) were non-mutagenic (in the absence of light) and non-photomutagenic (in the presence of light). Dihydroxyacetone (DHA), used as an active ingredient in self-tanning lotions, slightly increased the number of revertants in Salmonella typhimurium TA100 and TA102 in the absence of light. However, the relevance of these effects is equivocal, since they occurred at very high, cytotoxic concentrations (5000 micrograms/plate). Furthermore, these increases were not potentiated by light, thus demonstrating the non-photomutagenicity of DHA. In contrast, 7,12-dimethylbenz[a]anthracene (DMBA), which is non-mutagenic per se and is activated by external metabolizing systems (e.g., S9-mix) in the absence of light, was clearly mutagenic in Salmonella typhimurium TA98 and TA1537 in the presence of light (and the absence of S9-mix). Although the photomutagenic potency of DMBA, on a molar basis, was certainly lower than that of 8-MOP, the absolute mutagenic effects of DMBA in the respective bacterial strains were in a similar range under either S9-mix or photoactivation conditions. The strain specificity of the mutagenic effects were, however, different for either enzyme- or light-mediated mutagenicity. This indicates that different reactive intermediates are responsible for the mutagenicity in the tests using the two different activation systems. These results further suggest to use DMBA as a positive photomutagenic control compound alternatively to 8-MOP, since the latter is non- or only weakly photomutagenic in Salmonella typhimurium TA98 and TA1537. Furthermore, the usefulness and application of this photomutagenicity test system could be demonstrated for the testing of different photoabsorbing chemicals and cosmetic ingredients.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1996

Pregnancy-dependent growth of mammary tumors is associated with overexpression of insulin-like growth factor II.

We demonstrate that although IGF-II gene expression is approximately 3-fold higher in 9,10-dimethyl-1,2-benzanthracine (DMBA)-induced rat mammary tumors (MTs) than in nonneoplastic breast tissue, IGF-II mRNA abundance in DMBA-induced MTs is approximately 130-fold higher in pregnant as compared to nonpregnant hosts. This correlated with accelerated tumor growth in pregnant hosts. Immunohistochemical studies of DMBA-induced MTs with an anti-IGF-II antibody showed an intense staining of tumor cells for IGF-II, whereas a very low staining signal was observed for normal epithelial cells in the lobules. A similar immunostaining pattern was observed in three of three human ductal cancers and adjacent normal breast tissue obtained during pregnancy. DMBA-induced MTs expressed high levels of type I receptor for IGFs as determined by Northern blots. In vitro studies confirmed that IGF-II is a mitogen for neoplastic epithelial cells derived from DMBA-induced MTs. These results demonstrate that hormonal changes associated with pregnancy accelerate breast cancer cell proliferation in the DMBA-induced MT model and suggest that this acceleration is mediated by up-regulation of IGF-II expression within neoplasms.

9,10-Dimethyl-1,2-benzanthracene↗
PubMed1996

Lack of tumor promoting effects of KCB-1, a recombinant human basic fibroblast growth factor, on two-stage skin carcinogenesis in female CD-1 (ICR) mice.

Skin tumor promoting and co-promoting potentials of KCB-1, a recombinant human basic fibroblast growth factor, were investigated in a two-stage skin carcinogenesis model using female ICR mice. Animals were allocated to either normal (non-injured) or injured skin groups, and given a single topical application of dimethylbenz[alpha]anthracene (DMBA) at 100 micrograms/mouse to fur-clipped back skin. One week after the DMBA initiation step, mice were injected with KCB-1 (0.4, 4.0 and 40 micrograms/mouse, s.c.) and/or 12-O-tetradecanoylphorbol-13-acetate (TPA) at 4.0 micrograms/mouse twice a week until the termination at week 20. The treatment with KCB-1 was not associated with any increases of papillomas and hyperplasias in either the normal or the wounded skin cases. High incidences and multiplicities of skin papillomas and hyperplasias developed in TPA-treated groups. The positive control TPA promotion was not influenced by the KCB-1 treatment in the present initiation/promotion protocol. Thus, KCB-1 exerted no tumor promoting effects on mouse skin two-stage carcinogenesis, and also no amplification activity for the established skin tumor promoter TPA.

9,10-Dimethyl-1,2-benzanthracene↗